Trials / Completed
CompletedNCT03008343
Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
Detailed description
By enrolling patients with recurrent liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using IRE and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Irreversible Electroporation | One kind of electric ablation machine from Angiodynamic company (USA) |
| BIOLOGICAL | Natural killer | Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-12-01
- Completion
- 2019-07-01
- First posted
- 2017-01-02
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03008343. Inclusion in this directory is not an endorsement.